Stem Cell Therapy for ALS
- Written by
- StemCell Longevita Editorial Team
- Medically reviewed by
- Prof. Dr. Erdal Karaöz TeamProfessor of Histology and Embryology · Medical Director, Center for Regenerative Medicine
- Last reviewed
- Next scheduled review
How we evaluate evidence · Conflict-of-interest disclosure · Editorial standards
Advanced MSC treatments providing neuroprotection for motor neurons, reducing neuroinflammation, and slowing disease progression via combined IV and intrathecal delivery.
Can stem cell therapy help ALS?
Mesenchymal stem cell therapy is not an approved treatment for amyotrophic lateral sclerosis. Early- and mid-phase trials — including intrathecal MSC studies — have reported acceptable safety but have not demonstrated a consistent slowing of ALSFRS-R decline or survival benefit. Disease-modifying drugs, respiratory management and multidisciplinary care remain the interventions with proven benefit and should continue in parallel.
Key facts
- Approval status
- Not approved anywhere for ALS
- Trial findings
- Safety acceptable; ALSFRS-R benefit not consistent
- Standard care
- Riluzole/edaravone, respiratory and MDT support
What we know
- Intravenous and intrathecal MSC administration have been studied in ALS with short-term safety endpoints met.
What remains uncertain
- Whether any subgroup shows a measurable slowing of disease progression compared with placebo.
Medically reviewed questions
This summary is general medical information, not medical advice, and not a promise of benefit. Figures are quoted ranges, confirmed in writing after a medical review.
Medically reviewed by: Prof. Dr. Erdal Karaöz · Last updated: · Editorial and evidence policy
Evidence at a glance — Amyotrophic lateral sclerosis (ALS)
A plain summary of what the published research does and does not show for this condition. It is written to the same standard whether the evidence is strong or weak.
- Human studies available?
- Yes — including controlled studies
- Randomised trials?
- Randomised phase 2/3 trials completed; primary endpoints not met
- Main outcomes studied
- ALSFRS-R decline
- Respiratory function
- Survival
- Safety
- Long-term evidence
- Limited
- Regulatory approval for this indication
- United States (FDA): No FDA-approved mesenchymal stem cell product for this indication. The FDA has issued consumer warnings about unapproved stem cell products.
- European Union (EMA): No EMA-authorised mesenchymal stem cell medicine for this indication.
- United Kingdom (MHRA): No MHRA-authorised mesenchymal stem cell medicine for this indication.
- Türkiye (Ministry of Health): In Türkiye, cell therapies are delivered only inside Ministry of Health–licensed centres under the regenerative medicine / advanced therapy regulations, as clinical research or individual (exceptional) use — not as an approved routine treatment for this indication.
- Role at our centre
- Research context — considered only where standard care is exhausted or unsuitable, and never as a replacement for it
What kind of evidence exists
- Mechanism (laboratory): Documented
- Animal / preclinical: Documented
- Early human (phase 1/2, uncontrolled): Documented
- Controlled human (randomised or sham-controlled): Documented
- Regulatory approval: Not established
Sources
- Systematic reviews and meta-analyses — Amyotrophic lateral sclerosis (ALS) — PubMed
- Randomised controlled trials — Amyotrophic lateral sclerosis (ALS) — PubMed
- Registered MSC trials — Amyotrophic lateral sclerosis (ALS) — ClinicalTrials.gov
- FDA — Consumer alert on regenerative medicine therapies — U.S. Food and Drug Administration, 2024
- Advanced therapy medicinal products: overview — European Medicines Agency, 2025
- ISSCR Guidelines for Stem Cell Research and Clinical Translation — International Society for Stem Cell Research, 2021
- ISSCR Patient Handbook on Stem Cell Therapies — International Society for Stem Cell Research, 2020
Source links open filtered searches of PubMed and ClinicalTrials.gov plus regulator and professional-society pages, so you can read the current evidence yourself rather than a selected extract.
This summary is general information about the evidence base, not medical advice and not a promise of benefit. Whether any treatment is appropriate for you can only be decided after a medical review of your records.
What is ALS (Motor Neuron Disease)?
Amyotrophic lateral sclerosis (ALS), also known as motor neuron disease (MND) or Lou Gehrig's disease, is a progressive neurodegenerative disease that affects motor neurons in the brain and spinal cord. It leads to gradual loss of muscle control, affecting speech, swallowing, breathing, and movement.
ALS currently has very limited treatment options, with existing medications providing only modest slowing of progression. MSC therapy represents a promising frontier by providing neuroprotective factors, reducing the neuroinflammation that accelerates motor neuron death, and supporting remaining neural function.
At StemCell Longevita, we offer specialized ALS protocols using combined intrathecal and IV delivery of high-potency Wharton's jelly MSCs, designed to maximize neuroprotective effects and slow disease progression.
How Stem Cell Therapy Helps ALS (Amyotrophic Lateral Sclerosis)
Motor Neuron Protection
MSCs release neurotrophic factors (BDNF, GDNF, VEGF) that protect surviving motor neurons from further degeneration and support their function.
Neuroinflammation Control
MSCs modulate the inflammatory microenvironment around motor neurons, reducing microglial activation and toxic cytokine production that accelerate disease progression.
Progression Slowing
By protecting remaining motor neurons and reducing neuroinflammation, MSC therapy may slow the rate of functional decline in ALS patients.
Quality of Life
Many patients report stabilization or improvement in specific functional domains, maintaining independence in daily activities for longer periods.
Treatment Process
Your step-by-step treatment journey at StemCell Longevita
ALS Assessment
ALSFRS-R scoring, pulmonary function testing, EMG evaluation, and comprehensive neurological examination.
Treatment Planning
Individualized protocol based on disease stage, rate of progression, affected regions, and overall health status.
MSC Preparation
High-potency Wharton's jelly MSCs optimized for neuroprotective factor secretion, prepared in our GMP-certified laboratory.
Dual Delivery
Combined intrathecal injection near affected spinal segments plus IV infusion for maximum motor neuron protection.
Longitudinal Monitoring
ALSFRS-R scoring and functional assessments at 1, 3, 6 months to track disease stability and plan follow-up treatments.
Patient Experiences
Real outcomes from patients who chose regenerative medicine at StemCell Longevita Istanbul
"After 8 years of decline, I finally feel like I'm moving forward again. The team in Istanbul gave me something my neurologist at home couldn't — hope backed by real results."
"Within three months of treatment, our daughter started calling us by name. Her teachers noticed the difference before we even told them about the therapy."
Frequently Asked Questions
All Regenerative Medicine Applications
Explore our comprehensive range of regenerative medicine applications for various conditions. Click any option to learn more.
Related Articles
Explore our in-depth research articles and guides on related treatments and therapies.
Cerebral Palsy & Regenerative Medicine: New Hope for Children
Discover how mesenchymal stem cell approaches are supporting the care landscape for cerebral palsy, offering potential motor function improvement and quality of life for children and families worldwide.
Read ArticleRegenerative Medicine Application for Autism Spectrum Disorder
Explore the promising potential of regenerative medicine in addressing autism spectrum disorder symptoms, including potential improvements in communication, social interaction, and behavioral patterns.
Read ArticleStroke Progress: How Stem Cells Support Neurological Wellness
Exploring the potential of regenerative medicine in stroke rehabilitation, including mechanisms of action and reported improvements in motor and cognitive function.
Read ArticleRelated clinical questions
Where this page sits in the wider picture.